Pranita Tamma, MD, MPH
Pediatric Infectious Diseases
Highlights
Johns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Pranita Tamma
Primary Academic Title
Associate Professor of Pediatrics
Background
Pranita Tamma is an Associate Professor of Pediatrics in the Division of Pediatric Infectious Diseases at The Johns Hopkins University School of Medicine. As Medical Director of Antimicrobial Stewardship, she assists clinicians with optimizing the selection of antibiotics to improve patient outcomes while minimizing antibiotic-associated harm. She is the recipient of federal research funding that focuses on improving our understanding of the mechanisms of gram-negative bacterial resistance, improving available diagnostics to identify gram-negative resistant pathogens, and optimizing therapeutic choices for infections caused by multidrug-resistant gram-negative organisms, including novel therapies like phage therapy.
Research Interests
Diagnosing and treating multidrug-resistant infections, improving antibiotic use among children and adults
Research Summary
Dr. Tamma focuses on laboratory-based research and clinical trials to optimize treatment options for antimicrobial resistant infections. She was the recent recipient of a $14 million award focused on optimizing outcomes for adults with gram-negative bloodstream infections.
Selected Publications
Tamma PD, Beisken S, Bergman Y, Posch AE, Avdic E, Sharara S, Cosgrove SE, Simner PJ. Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance. Clin Infect Dis. 2021;73(11):e4599-e4606.
Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AF, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice- Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers HF, Fowler VG, Schooley RT. Safety and Microbiological Activity of Phage Therapy in Persons with Cystic Fibrosis Colonized with Pseudomonas aeruginosa: Study Protocol for a Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Trials. 2022;23(1):1057
Amoah J, Klein EY, Chiotos K, Cosgrove SE, *Tamma PD. Administration of a β-lactam Prior to Vancomycin as the First Dose of Antibiotic Therapy Improves Survival in Patients with Bloodstream Infections. Clin Infect Dis. 2022;75(1):98-104
Simner PJ, Mostafa HH, Bergman Y, Ante M, Tekle T, Adebayo A, Beisken S, Dzintars K, Tamma PD. Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy Is Associated with Increased blaNDM-5 Copy Number and Gene Expression. Clin Infect Dis. 2022;75(1):47-54.
Simner PJ. Bergman Y, Conzemius R, Jacobs E, Tekle T, Beisken S, Tamma PD. An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Towards Pan-β-Lactam Resistance. Open Forum Infect Dis. 2023
Honors
National Gale and Ira Drukier Prize in Children's Health Research, Weill Cornell Medicine
Memberships
- Society for Healthcare Epidemiology of America
- The Pediatric Infectious Diseases Society
- Infectious Diseases Society of America
Locations
- The Johns Hopkins Hospital
- 1800 Orleans Street, Baltimore, MD 21287
- phone: 410-955-5000
- fax: 410-955-5001
Expertise
Education
Johns Hopkins University School of Medicine
Fellowship, Pediatric Infectious Diseases, 2011Johns Hopkins Bloomberg School of Public Health
Graduate School, Clinical Investigation, MHS, 2011Johns Hopkins University School of Medicine
Residency, Pediatrics, 2007SUNY Downstate Medical Center
Medical Education, MD, 2004Board Certifications
Pediatric Infectious Diseases
American Board of Pediatrics, 2011Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Humana
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- UnitedHealthcare
- Veteran Affairs Community Care Network (Optum-VACCN)